Ventyx set for record day as oral drug reduces heart disease risk markers in trial

Ventyx Biosciences

23/10/2025 15:29

Updates

Updates

** Shares of drug developer Ventyx Biosciences VTYX.O rise as much as 102.6% to $7.82, their highest in nearly two years

 ** Stock set for its biggest one-day pct. rise ever, if gains hold

** Ventyx late on Wednesday said its oral drug VTX3232 cut key inflammation markers tied to heart disease in patients with obesity and cardiovascular risk

** VTYX said its drug lowered hsCRP, an important heart risk marker, by about 80% in the first week

** "Reductions in inflammatory markers are encouraging, but additional Phase 2/3 trials in different cardiovascular indications are needed, given the lack of effect on weight loss," said H.C. Wainwright

 ** Brokerage says VNTX awaits Sanofi's SASY.PA decision on a partnership for larger trials - essential for advancing VTX3232 in major heart disease studies

** Co said combination with Novo Nordisk's semaglutide led to further reductions in inflammation markers, but did not boost weight loss

** Including session's move, stock up 229.2% YTD

(Reporting by Sahil Pandey in Bengaluru)

((Sahil.Pandey@thomsonreuters.com))